MiFID medicine may be poison for small firms, warns Nordea AM

The head of Nordea Asset Management says new rules targeting conflicts of interest in his industry are hurting smaller fund managers as they struggle to keep up with the demands.

Nils Bolmstrand Head of Nordea Asset Management is worried about smaller asset managers ability to pay for research after implementation of MIFID II.

Log in to read our articles

Welcome to AMWatch. A part of our content is exclusive and reserved for our users.

Try AMWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles

amwatch trial

Latest news


See all

See all

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch